| Objective: To explore the therapeutic effect of Zuogui Pill combined with zoledronic acid on OP patients with kidney deficiency and essence deficiency.So as to provide detailed and reliable scientific basis for the clinical treatment of OP patients.Methods: This study is a retrospective controlled study.A total of 95 patients(cases)of OP patients who were admitted to the Department of Orthopedics of Sichuan Provincial Hospital of Traditional Chinese Medicine from September 2019 to September 2020 were selected and belonged to the "Kidney Deficiency Essence Deficiency Type".According to the relevant criteria for inclusion and exclusion,And divided them into three groups: A,B,and C,with 32 cases in group A,31 cases in group B,and 32 cases in group C.Patients in group A were treated with Zuogui pill,patients in group B were treated with zoledronic acid,and patients in group C were treated with Zuogui pill + zoledronic acid.These three groups received routine treatment before and after treatment.Anti-OP treatment.Among them,2 cases were lost to follow-up in group A,1 case was lost to follow-up in group B,2 cases were lost to follow-up in group C,and 30 people in group A,30 people in group B,and 30 people in group C totaled 90 patients.The average age of patients in group A was 75.2±5.95 years;the average age of patients in group B was76.73±5.51 years;the average age of patients in group C was 74.53±5.01 years.Among them,30 were males and 50 were females.After the treatment,the clinical data of the three groups of patients were analyzed,and the VAS score,SPPB score,ODI score,TCM syndrome score and BMD level of each group were compared.Results:(1)In the cases of these three groups,the gender,age,VAS score,ODI score,SPPB score,TCM syndrome score and BMD of each patient were not comparable before the start of treatment(P>0.05).(2)VAS score: The VAS score values ??of patients in each group after treatment were significantly reduced compared to before treatment,which is statistically significant(P<0.05);after 4 weeks of treatment There is no difference between group C and groups A and B(P=0.386>0.05);after 12 weeks of treatment,group C is better than groups A and B(P=0.000,PB-C=0.000<0.05,PA-C=0.000 <0.05),there is no difference between group A and group B(PA-B=0.089>0.05);after 24 weeks of treatment,group C is better than groups A and B(P=0.000,PB-C=0.000<0.05,PA-C=0.000<0.05),there is no difference between group A and group B(PA-B=0.098>0.05).(3)ODI score: The ODI score values ??of patients in each group after treatment were significantly reduced compared to before treatment,which was statistically significant(P<0.05);treatment 4 Weeks later,group C was better than groups A and B(P=0.008,PB-C=0.003<0.05,PA-C=0.019<0.05),and there was no difference between group A and group B(PA-B=0.531>0.05);After 12 weeks of treatment,group C is better than group A and B(P=0.000,PB-C=0.000<0.05,PA-C=0.000<0.05),group A is better than group B(PA-B=0.044 < 0.05));after 24 weeks of treatment,group C is better than group A and B(P=0.000,PB-C=0.000,PA-C=0.000),group A is better than group B(PA-B=0.002<0.05).(4)TCM syndrome score:After treatment,the TCM syndrome score values ??of patients in each group have been significantly reduced compared to before treatment,which is statistically significant(P<0.05);treatment After 4 weeks,group C was better than groups A and B(P=0.005,PB-C=0.003<0.05,PA-C=0.008<0.05),there was no difference between group A and group B(PA-B=0.782>0.05);after 12 weeks of treatment,group C was better than group A and group B(P=0.000,PB-C=0.001<0.05,PA-C=0.002<0.05),there was no difference between group A and group B(PA-B= 0.687>0.05);after 24 weeks of treatment,group C is better than group A and B(P=0.000,PB-C=0.000<0.05,PA-C=0.001<0.05),group A is better than group B(PA-B =0.014<0.05).(5)SPPB score: After treatment,the SPPB score of patients in each group was significantly lower than before treatment,which was statistically significant(P<0.05);after 4 weeks of treatment,group C was better than group A,Group B(P=0.018,PB-C=0.049<0.05,PA-C=0.038<0.05),there is no difference between group A and group B(PA-B=0.927>0.05);after 12 weeks of treatment,group C Better than groups A and B(P=0.001,PB-C=0.004<0.05,PA-C=0.003 < 0.05),there is no difference between group A and group B(PA-B=0.918>0.05);after 24 weeks of treatment,Group C is better than groups A and B(P=0.000,PB-C=0.000,PA-C=0.001),and there is no difference between group A and group B(PA-B=0.671<0.05).(6)BMD: After treatment,the BMD scores of patients in each group were significantly higher than before treatment,which is statistically significant(P<0.05);after 24 weeks of treatment,group C It is better than group A and group B(P=0.020,PB-C=0.036<0.05,PA-C=0.008<0.05),and there is no difference between group A and group B(PA-B=0.569>0.05).Conclusion: Zuogui pill combined with zoledronic acid can significantly reduce the body pain of OP patients with kidney deficiency and essence deficiency,restore physical function,and improve BMD level,thereby significantly improving the quality of daily life of the patient,the treatment effect is accurate,and it is worthy of clinical practice It is widely used. |
PDF Full Text Request